Theravance hires Michael E. Faerm as Chief Business Officer

Theravance, Inc. has hired former Wells Fargo Securities Senior Pharmaceuticals Equity Research Analyst Michael E. Faerm as Senior VP and Chief Business Officer, the company announced.

Theravance President and CEO Michael W. Aguiar said, “Michael brings a unique perspective with his depth and breadth of experience in the biopharmaceutical industry, equity research and investment banking. His experience and relationships will strengthen the Theravance team as we continue to work closely with GlaxoSmithKline to maximize the value of Relvar/Breo Ellipta and Anoro Ellipta and begin to focus on increasing the duration and terminal value of our product portfolio.”

GSK and Theravance announced the initiation of a Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol DPI for the treatment of COPD earlier this year.

Read the Theravance press release.